Proteasome Inhibition in Transplantation-Focusing on the Experience with Bortezomib

Author(s): Yong Liang, Haiyan Liu

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 18 , 2013

Become EABM
Become Reviewer
Call for Editor


The proteasome inhibition has been proved to be effective in the treatment of multiple myeloma and other malignancies. In addition to direct antitumor effects, proteasome inhibition also exerts strong effects on immune cells, such as T cells, B cells and DCs. Therefore, proteasome inhibition, through the utilization of small molecule drugs like bortezomib, could be used therapeutically to modulate immune responses in transplantation. In the current review, we discuss the emerging data, both preclinical and clinical, of using proteasome inhibition in treating complications of transplantation, such as antibody-mediated organ rejection (AMR) and graft-versus-host disease (GVHD). The therapy based on proteasome inhibition may present substantial opportunities as new therapeutic paradigms in transplantation.

Keywords: Immunosuppression, proteasome, proteasome inhibitors, T cells, bortezomib, transplantation, B cells, DCs.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 31 March, 2013
Page: [3299 - 3304]
Pages: 6
DOI: 10.2174/13816128113199990308
Price: $65

Article Metrics

PDF: 19